Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Executive summary

Burden of Moderate-to-severe plaque psoriasis

6 evidence topics · 61 sources

Summary: prevalence and moderate-to-severe fraction

Two U.S. national surveys each estimate adult psoriasis prevalence at 3.0%:

  • 2023 National Health Interview Survey: approximately 3.0% of adults aged 18 years and older reported a history of psoriasis (942 of 29,486 participants), or approximately 7.9 million U.S. adults in 2023.
  • NHANES 2011-2014: 3.0% (95% CI, 2.6% to 3.4%) of adults aged 20 years or older, or approximately 7.55 million adults based on 2020 census data. Among adults aged 20 to 59 years, the 2011-2014 estimate of 2.9% did not differ statistically from 2.9% in the 2009-2010 cycle and 3.2% in the 2003-2004 cycle (P = .84).
  • An analysis of NHANES 2003-2006 and 2009-2014 and the 2023-2024 National Health Interview Survey (53,225 participants) found no temporal trend in prevalence in any sociodemographic subgroup.
  • A separate estimate for U.S. adults aged 20 to 59 years gives a diagnosed prevalence of 3.15% (5 million adults) and an undiagnosed active prevalence of 0.4% (approximately 600,000 adults). U.S. claims-based prevalence ranged from 0.51% to 1.23% depending on the identification algorithm.

Estimates of the moderate-to-severe fraction:

  • NHANES 2011-2014: 21.5% of participants reported moderate to severe psoriasis (≥3 palms of body surface area involvement), and the majority reported little or no psoriasis at the time of the survey.
  • U.S. adults aged 20 to 59 years: 16.63% of those with a physician diagnosis had moderate to severe disease (3% or greater BSA), an estimated 1.4 million people, and 2.1 million considered psoriasis a large problem in daily life.
  • Another analysis: 18.2% (95% CI 12.4 to 25.9) reported moderate or severe disease, 27.3% mild disease, and 54.5% no or little disease.
  • Claims analyses: 27.3% moderate to severe and 70.9% mild in one; in another, which assigned severity by treatment type, an estimated 1.7 million insured U.S. patients had moderate to severe psoriasis, of whom 1 million (59%) were not treated in the preceding year.

Globally, 42.98 million people had psoriasis in 2021 in GBD 2021, an increase of approximately 86.4% from 1990, and a separate estimate puts the worldwide number at approximately 125 million. Regional prevalence ranged from 0.14% in east Asia to 1.99% in Australasia, with 1.50% in high income North America.

Summary: incidence, natural history, and mortality
  • Incidence: in a retrospective cohort identified with electronic health records from 2014 to 2018 (population 2,152,192), incidence was 63.8 (95% CI 61.8 to 65.8) per 100,000 person-years and stable over the 5-year period; it peaked at 92.3 per 100,000 person-years at ages 70 to 79 years and was 75.3 in White, 52.2 in Hispanic/Latino, and 24.9 per 100,000 person-years in Black patients. In a psoriasis cohort whose survival was compared with the Minnesota white population, the age- and sex-adjusted annual incidence was 78.9 per 100,000 and rose from 50.8 per 100,000 in 1970–74 to 100.5 per 100,000 in 1995–1999.
  • Incidence across countries and worldwide: adult incidence ranged from 30.3 per 100 000 person years in Taiwan to 321.0 per 100 000 person years in Italy. GBD 2021 counted 5.10 million incident cases worldwide in 2021, a 78.76% increase since 1990, with 8.25 million projected for 2036. An analysis of 1990 to 2019 reported a decrease in the global age-standardized rate (ASR) of psoriasis (AAPC = −0.77), with decreases in all 21 regions.
  • Natural history: psoriasis is described as a lifelong disease that “cannot currently be cured”. Onset is bimodal, with peaks around 18-29 and 50-59 years in women and 30-39 and 60-69 or 70-79 years in men; mean age at diagnosis was 43.2 years in the Minnesota-compared cohort.
  • Mortality: in one study, severe psoriasis was associated with increased overall mortality (HR, 1.5; 95% CI, 1.3-1.7) and mild psoriasis was not (HR, 1.0), and men and women with severe psoriasis died 3.5 and 4.4 years younger than people without psoriasis. Cause-specific hazard ratios in severe psoriasis were 1.57 for cardiovascular disease, 1.41 for malignancies, 1.65 for infection, and 4.37 for kidney disease, with one extra cardiovascular death per 283 patients per year. Across 12 studies, pooled all-cause mortality RRs were 1.21 in psoriasis, 1.13 in mild psoriasis, and 1.52 in severe psoriasis, and cardiovascular mortality RRs of 1.15, 1.05 (95% CI 0.92-1.20), and 1.38. Another study reported an adjusted HR of 1.99 (95% CI, 1.01-3.93) over a median follow-up of 52.3 months, while survival in the Minnesota-compared cohort was similar to that expected (SMR 0.95, 95% CI 0.84 to 1.07).
Summary: comorbidities
  • Psoriatic arthritis: across 266 studies of 976,408 people with psoriasis, the pooled proportion with PsA was 19.7% (95% CI, 18.5%-20.9%), and 19.5% in North American patients; PsA incidence ranged from 0.27 to 2.7 per 100 person-years. In a cohort of 464 participants followed for 8 years, 51 developed PsA (annual incidence 2.7 per 100 psoriasis patients), and a severe psoriasis phenotype and nail pitting were among the predictors. In most patients, psoriasis precedes joint disease by up to 10 years. PsA was present in 22.1% of 5,492 people with moderate-to-severe psoriasis in OptumHealth claims.
  • Cardiovascular disease: myocardial infarction incidence per 1000 person-years was 3.58 in controls, 4.04 in mild psoriasis, and 5.13 in severe psoriasis, and the adjusted RR of myocardial infarction with severe psoriasis was 3.10 at age 30 and 1.36 at age 60. Severe psoriasis was associated with cardiovascular mortality (RR, 1.39), myocardial infarction (RR, 1.70), and stroke (RR, 1.56), and psoriasis with an estimated excess of 11,500 major adverse cardiovascular events each year.
  • Metabolic disease: psoriasis was associated with diabetes (OR 1.59; 1.53 in mild and 1.97 in severe psoriasis; RR 1.27 for incident diabetes), metabolic syndrome (OR 2.26, with a dose-response relationship by severity), and non-alcoholic fatty liver disease (OR 1.96). In the OptumHealth claims cohort, hyperlipidemia (33.3% vs. 27.3%), hypertension (32.8% vs. 23.5%), diabetes (15.8% vs. 9.7%), and obesity (4.8% vs. 2.3%) were more frequent than in matched controls.
  • Inflammatory bowel disease: odds ratios were 1.70 for Crohn disease and 1.75 for ulcerative colitis.
  • Depression and anxiety: the prevalence of depressive symptoms was 28% by questionnaire and of clinical depression 12% by ICD codes, and population-based studies gave an OR of 1.57 for depression. In a UK cohort, adjusted hazard ratios for depression, anxiety, and suicidality were 1.39, 1.31, and 1.44, and the hazard ratio for depression was 1.72 in severe and 1.38 in mild psoriasis. Anxiety symptoms had a pooled prevalence of 34% across 101 studies. Among survey respondents with psoriasis or PsA, 52% screened positive for potential major depressive disorder (PHQ-2 score ≥ 3), and depression and anxiety affected 9.1% and 6.3% of the OptumHealth claims cohort.
Summary: humanistic burden
  • Quality of life: in the UPLIFT online survey in North America, Europe, and Japan, respondents with PsO and/or PsA (n = 3614) had a mean DLQI of 9.3, and the proportion with DLQI > 5 was 56% with limited BSA (≤ 3 palms), 80% with moderate BSA (4–10 palms), and 88% with large BSA (> 10 palms). Among 1529 registry participants on systemic therapy as of 31 May 2016, mean DLQI ranged from 5.2 to 10.2 and mean EQ-VAS from 62.9 (very severe) to 76.4 (mild) across BSA categories. In a U.S. survey of 694 participants, DLQI was higher by 2.97 (moderate vs. mild) and 7.95 (severe vs. mild) and EQ-5D lower by 0.04 and 0.18. In a meta-analysis of 70 utility scores from 59 studies (22 for plaque psoriasis), the mean EQ-5D utility score for plaque psoriasis was 0.755.
  • Itch: 92.9% of patients reported pruritus at some time in the course of psoriasis and 81% within the preceding 3 days; in another study, 43% of psoriasis patients named itching as their most bothersome sign or symptom, and 93% of National Psoriasis Foundation survey respondents reported regular pruritus. Mean itching scores ranged from 24.7 to 55.7 across BSA categories in the registry.
  • Emotional effects and stigma: among 5,604 National Psoriasis Foundation survey respondents from 2003 to 2011, psoriasis and PsA affected emotional wellbeing in 88%, 87% reported embarrassment, and 83% concealed physical manifestations; 51% of conversations about psoriasis contained negative comments from others. In a U.S. online survey of 793 participants from 2020 to 2021, psoriasis affected emotional well-being in 87% and quality of life in 91%, 36% had been asked if they were contagious, 34% had been stared at in public, and 21% avoided having sex because of their condition or could not stand the thought of someone touching or seeing their skin. In a clinic survey of 106 participants, patient-reported severe psoriasis was associated with “greater anticipation of negative stereotypes, social avoidance, and perceived stigma from others”, and physician-measured BSA and global assessment scores were not significantly associated with any outcome. Psoriasis was associated with sleep disturbance (OR 6.640) across 15 studies.
  • Work: in the 2015 Adelphi survey of 936 respondents in the U.S. and five European countries, mean total work productivity loss was 10.1%, 18.9%, and 29.4% in mild, moderate, and severe psoriasis, and mean annual indirect costs per patient were 9591 U.S. dollars in the U.S. In the registry, 7% to 14% were disabled across BSA categories. Among National Psoriasis Foundation survey respondents, 12% were unemployed, of whom 92% cited psoriasis and/or PsA as the sole reasons, and 49% of working respondents missed work days regularly. In the 2020 to 2021 online survey, 29% could not work or study in the week before the survey.
Summary: economic burden
  • National cost: a review of 22 studies estimated the annual U.S. cost of psoriasis at approximately $112 billion in 2013, with direct costs of $51.7 billion to $63.2 billion, indirect costs of $23.9 billion to $35.4 billion, and $36.4 billion attributed to medical comorbidities. A second estimate put the total 2013 burden at $35.2 billion for 7.4 million people: $12.2 billion in incremental medical costs, $11.8 billion from reduced HRQOL, and $11.2 billion from productivity losses.
  • Costs by severity: in OptumHealth claims from 2007 to 2012 (2012 U.S. dollars), patients with moderate-to-severe psoriasis (≥ 1 systemic therapy or phototherapy) incurred annual total health care costs of $22,713 vs. $4,993 in matched controls (adjusted difference $18,960), including $14,698 vs. $1,101 for medications; psoriasis-related costs averaged $13,731, of which $12,958 was for systemic therapies. In MarketScan claims from 2009 to 2014 (2014 U.S. dollars), all-cause costs were $12,523 per patient per year overall, $21,481 with moderate-to-severe disease, $23,427 with PsA, and $29,832 on biologics. Another claims study (2019 U.S. dollars) reported annual all-cause costs of $7,470, $11,062, and $29,742 for controls, psoriasis, and PsA. Among 2,130 biologic-treated people, median all-cause total costs were $37.7k (mild), $42.3k (moderate), and $49.3k (severe). At nine U.S. sites, six-month direct costs of moderate-to-severe plaque psoriasis (MSPP) were $11,291 and indirect costs $2101 per patient among 200 adults seeking MSPP treatment.
  • Costs by treatment: annual medication costs were $21,977 for biologics and $3413 for oral systemics in U.S. dermatology records. Among patients initiating biologics, the average annual treatment cost, estimated from net prices accounting for average manufacturer rebates, rose from $21,236 in 2007 to $47,125 in 2021, with a 2021 range of $12,413 (infliximab) to $70,043 (risankizumab); initiating the lowest-cost medication in each class would have lowered the 2021 average by 44% ($26,363). Compared with nonswitchers, biologic switchers had higher adjusted total costs (mean difference $10,120) and discontinuers lower costs (−$18,611).
  • Comorbidity and work costs: compared with controls, psoriasis patients incurred higher total health care costs by $1,590, $5,870, and $18,427 with 0, 1-2, and ≥3 comorbidities, and higher work-loss costs by $335, $655, and $1,695. Per patient per month cost differences in moderate to severe psoriasis included $372 for mental health, $305 for hypertension, and $360 for liver disease. Among 452 employed participants of the CLEAR trial, mean annual indirect costs per worker were $10,318 with PASI < 50 and $2,233 with PASI ≥ 90.
  • Out-of-pocket spending: survey respondents reported mean out-of-pocket costs of $240 per month for healthcare and $147 per month for nonprescription medicines, creams, and lotions.
Summary: burden on families
  • Among 63 relatives and partners, seventy percent spent extra time on housework because of the patient's treatment, 57% described psychological pressures, 55% social disruption, and 37% deterioration of close relationships; 8% described no effect on their quality of life. Their quality of life correlated more closely with the patient's DLQI (r = 0.77) than with PASI (r = 0.34).
  • In a prospective study of 556 people with psoriasis and their partners at 11 centers in Austria, Canada, Germany, Italy, Spain, and Turkey, partner burden increased with severity in each domain, with the highest scores for emotional strain and cleaning.
  • Of 153 close relatives and partners of 250 registry participants with mostly treatment-controlled disease, 78.7% of male and 77.3% of female relatives and partners had a small or larger disease burden.
  • Psoriasis impaired the quality of life of 87.8% of cohabitants, whose FDLQI scores correlated with patients' DLQI scores (rs = 0.554).
  • In a clinic sample of 83 participants, family income correlated negatively with severity (Spearman's rho = -0.356); mean PASI was 20.5 with family income below the social minimum and 11.7 with higher income.
  • Across 21 studies of 1161 caregivers of children with psoriasis, 96.1% of caregivers experienced some degree of HrQOL impairment, which correlated with child disease severity (r = 0.463).